229 related articles for article (PubMed ID: 9241650)
1. PET FDG studies in oncology.
Hawkins RA; Hoh CK
Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
[TBL] [Abstract][Full Text] [Related]
2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
3. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of FDG-PET in oncology.
Czernin J
Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
[TBL] [Abstract][Full Text] [Related]
5. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
Macfarlane DJ; Cotton L; Ackermann RJ; Minn H; Ficaro EP; Shreve PD; Wahl RL
Radiology; 1995 Feb; 194(2):425-9. PubMed ID: 7824722
[TBL] [Abstract][Full Text] [Related]
6. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
Giorgetti A; Volterrani D; Mariani G
Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
[TBL] [Abstract][Full Text] [Related]
7. Development of oncology protocol using fluorine-18-FDG: one center's experience.
Cronin V; Galantowicz P; Nabi HA
J Nucl Med Technol; 1997 Mar; 25(1):66-9. PubMed ID: 9239608
[TBL] [Abstract][Full Text] [Related]
8. The role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) whole body scan (WBS) in the staging and follow-up of cancer patients: our first experience.
Ferlin G; Rubello D; Chierichetti F; Zanco P; Bergamin R; Trento P; Fini A; Cargnel S
Tumori; 1997; 83(3):679-84. PubMed ID: 9267488
[TBL] [Abstract][Full Text] [Related]
9. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
[TBL] [Abstract][Full Text] [Related]
10. Use of positron emission tomography in oncology.
Glaspy JA; Hawkins R; Hoh CK; Phelps ME
Oncology (Williston Park); 1993 Jul; 7(7):41-6, 49-50; discussion 50-2, 55. PubMed ID: 8347460
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
Brock CS; Meikle SR; Price P
Eur J Nucl Med; 1997 Jun; 24(6):691-705. PubMed ID: 9169580
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma.
Wong WL; Chevretton EB; McGurk M; Hussain K; Davis J; Beaney R; Baddeley H; Tierney P; Maisey M
Clin Otolaryngol Allied Sci; 1997 Jun; 22(3):209-14. PubMed ID: 9222623
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
15. [Cancer detection with whole-body FDG PET images without attenuation correction].
Yasuda S; Ide M; Takagi S; Shohtsu A; Mitomi T; Kobayashi S; Suzuki Y
Kaku Igaku; 1996 Apr; 33(4):367-73. PubMed ID: 8683875
[TBL] [Abstract][Full Text] [Related]
16. PET and [18F]-FDG in oncology: a clinical update.
Conti PS; Lilien DL; Hawley K; Keppler J; Grafton ST; Bading JR
Nucl Med Biol; 1996 Aug; 23(6):717-35. PubMed ID: 8940714
[TBL] [Abstract][Full Text] [Related]
17. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
[TBL] [Abstract][Full Text] [Related]
18. PET scans of abdominal malignancy.
Blahd WH; Brown CV; Khonsary SA; Farahi JB; Quinones N; Ribe JY; Coyle JJ; Glass EC; Mandelkern MA
World J Surg; 1996 Feb; 20(2):245-7. PubMed ID: 8661826
[TBL] [Abstract][Full Text] [Related]
19. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
Kubota K
Ann Nucl Med; 2001 Dec; 15(6):471-86. PubMed ID: 11831394
[TBL] [Abstract][Full Text] [Related]
20. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging?
Hoegerle S; Juengling F; Otte A; Altehoefer C; Moser EA; Nitzsche EU
Radiology; 1998 Oct; 209(1):253-8. PubMed ID: 9769840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
